


# Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma

## Supplementary Materials



**Supplementary Figure S1: *PRMT1* mRNA expression as a significant independent prognostic marker in primary neuroblastomas.** (A) High *PRMT1* expression is prognostic for poor survival and aggressive behavior in neuroblastoma patients. Kaplan-Meier analysis of overall survival for the Kocak dataset. The graph was downloaded from R2 microarray analysis and visualization platform (<http://r2.amc.nl>). Patients with higher *PRMT1* expression are highlighted in blue, whereas patients with lower *PRMT1* expression are highlighted in red. The log-rank test *P* values are indicated. (B) Box plot of *PRMT1* expression levels in stage (ST) 1-4S tumors. One-way analysis of variance (ANOVA),  $**P < 0.01$ . (C) YY plot showing the correlation of *MYCN* (red) and *PRMT1* (blue) mRNA levels in neuroblastoma tumor series Kocak dataset. Below the graph tracks for age, *MYCN* amplification, and International Neuroblastoma Staging System stages are shown.